Search results
Showing 7696 to 7710 of 8314 results
Lenus COPD Support Service for remotely managing chronic obstructive pulmonary disease (MIB300)
This advice has been updated and replaced by NICE healthtech guidance 736.
Space from Depression for treating adults with depression (MIB215)
This advice has been updated and replaced by NICE HealthTech guidance 675.
Discontinued Reference number: GID-TA11008
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.
Improving supportive and palliative care for adults with cancer (CSG4)
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.
This guidance has been replaced by NICE guideline NG17.
Farco-fill Protect for indwelling urinary catheterisation (MIB121)
July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.
We have moved Diagnostics guidance 8 to become HealthTech guidance 315. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 9 to become HealthTech guidance 316. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)
We have moved Diagnostics guidance 16 to become HealthTech guidance 360. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 13 to become HealthTech guidance 348. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
New sepsis guideline targets faster, tailored treatments to benefit patients
Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.
New AI tools could help save lives by spotting warning signs of bowel cancer earlier
Five smart technologies that act as a "second pair of eyes" during bowel examinations have been conditionally recommended by NICE for NHS use, potentially helping doctors spot harmful growths that could turn into cancer.
Fertility clinics must end unproven treatments that don't help couples have babies
Fertility clinics should not offer unproven treatments that do not help people have babies, our independent committee has recommended in draft guidance.